Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS).
At week 16, brivekimig demonstrated clinically meaningful improvements in both the primary endpoint—Hidradenitis Suppurativa Clinical Response (HiSCR50)—and key secondary endpoints compared to placebo. The treatment was well tolerated, with no serious adverse events reported. These findings will be presented in an oral session at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris.
Hidradenitis suppurativa is a chronic and debilitating inflammatory skin disease characterized by painful cutaneous nodules, abscesses and draining tunnels.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.